Prevep

Prevep is a biotechnology company focused on the development of long-acting therapeutics for the prevention and treatment of infectious diseases, with a primary emphasis on HIV. The company's lead program is a novel, long-acting small molecule formulation designed to simplify pre-exposure prophylaxis (PrEP) regimens and improve patient adherence. By leveraging advanced drug delivery technologies, Prevep aims to provide sustained-release options that reduce the frequency of dosing compared to current daily oral therapies. The company is currently advancing its lead candidate through early-stage clinical trials to evaluate safety, tolerability, and pharmacokinetic profiles.